-

Accelerator Life Science Partners Mourns the Loss of Senior Advisor and Friend, Tadataka "Tachi" Yamada, M.D.

SEATTLE--(BUSINESS WIRE)--Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today acknowledged the sudden passing of senior advisor and board member, Tadataka (Tachi) Yamada, M.D., who died unexpectedly at home on August 4, 2021.

“We are saddened to share the news of Tachi’s unexpected passing,” said Thong Q. Le, CEO and Senior Managing Director. “I have had the privilege and honor to have known and worked closely with Tachi for many years, and I was grateful to have the benefits of his knowledge, experience and leadership at ALSP. Tachi understood well the many challenges that early-stage biotechnology companies often face when developing disruptive technologies, and always reminded us to consider how the treatments we were developing would affect patients and (more broadly) global health. He is a 'giant among giants' when it comes to our life sciences industry, and his impact on patients and global health will be felt for many years to come. The ALSP team and I will miss Tachi dearly, and we send our deepest, most heartfelt sympathies to the Yamada family during this difficult time.”

About Accelerator Life Science Partners

Accelerator Life Science Partners (ALSP) is an investment firm that catalyzes the development and commercialization of breakthrough biotechnology innovations by providing the complete business, scientific, and financial toolkit necessary for accelerating the establishment and operation of early-stage biotechnology companies. ALSP’s portfolio companies are backed by some of the world’s leading pharmaceutical companies and comprise of industry-leading, transformative companies, including Lodo Therapeutics (acquired by Zymergen), Lydian Neurosciences, Magnolia Neurosciences, Petra Pharma (acquired by a global pharmaceutical company), and Rodeo Therapeutics (acquired by Amgen Inc.). ALSP is a minority-owned firm that seeks to promote diversity and inclusion in the healthcare industry. For more information, please visit www.acceleratorlsp.com.

Contacts

Accelerator Life Science Partners
Jessica Burback – jburback@acceleratorlsp.com
T: 206-234-6481

Accelerator Life Science Partners

Details
Headquarters: Seattle, WA
CEO: Thong Q. Le
Employees: 10
Organization: PRI

Release Versions

Contacts

Accelerator Life Science Partners
Jessica Burback – jburback@acceleratorlsp.com
T: 206-234-6481

More News From Accelerator Life Science Partners

ALSP Orchid Acquisition Corporation I Announces it Will Redeem its Public Shares and Will Not Consummate an Initial Business Combination

SEATTLE--(BUSINESS WIRE)--ALSP Orchid Acquisition Corporation I (Nasdaq: ALOR) (the “Company” or “ALSP Orchid”) announced today that it will redeem all of its outstanding Class A ordinary shares (the “Public Shares”), effective as of the close of business on November 14, 2023 or as soon as possible thereafter because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association (the “Articles”)....

Accelerator Life Science Partners Expands Executive Team with Appointment of Alice Chen as Executive Vice President

SEATTLE--(BUSINESS WIRE)--Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today announced that it has strengthened its executive leadership team with the promotion of Alice Chen, Ph.D., to executive vice president and the addition of Ronald Howell as Senior Advisor. This expansion enables the firm to better serve a broader, more diverse range of scientific founders and entrepreneurs in the life science community. Dr. Chen has more...

Accelerator Life Science Partners’ Portfolio Company Lodo Therapeutics Acquired by Zymergen Inc.

SEATTLE--(BUSINESS WIRE)--Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today announced that its portfolio company, Lodo Therapeutics Corporation ("Lodo" or the "Company"), has been acquired by Zymergen Inc. (NASDAQ: ZY) for an undisclosed amount. The transaction is the third exit from ALSP’s investment fund, Accelerator Life Science Partners I (ALSP I), in the last year. Lodo Therapeutics discovered and developed novel therapeut...
Back to Newsroom